CLINICAL TRIALS PROFILE FOR MT-7117
✉ Email this page to a colleague
Clinical Trials for MT-7117
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT02834442 ↗ | A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-7117 in Healthy Subjects | Completed | Mitsubishi Tanabe Pharma Corporation | Phase 1 | The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of MT-7117 in healthy subjects. |
| NCT03503266 ↗ | Mass Balance Study With MT-7117 | Completed | Mitsubishi Tanabe Pharma Development America, Inc. | Phase 1 | This is a single-centre, open-label, mass balance study in healthy male subjects utilising a single oral dose of [14C] MT 7117. |
| NCT03520036 ↗ | Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria | Completed | Mitsubishi Tanabe Pharma Development America, Inc. | Phase 2 | The purpose of this study is to investigate the efficacy and safety of MT-7117 on sunlight exposure duration without symptoms and tolerance in subjects with EPP. |
| NCT03688022 ↗ | Relative Bioavailability and Drug-drug Interaction Study With MT-7117 and a Proton Pump Inhibitor | Completed | Mitsubishi Tanabe Pharma Development America, Inc. | Phase 1 | An open label, multicentre, randomised, 2-cohort, sequential and crossover study to assess the relative oral bioavailability of MT-7117 higher content tablets versus MT-7117 lower content tablets and the pharmacokinetics of MT-7117 under various gastric conditions (fed and fasted, and following administration of a proton pump inhibitor and an acidic beverage) in healthy subjects |
| NCT04116476 ↗ | Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function | Completed | Mitsubishi Tanabe Pharma Development America, Inc. | Phase 1 | An Open-label, Single-center, Parallel-group Study to Assess Pharmacokinetics, Safety, and Tolerability of a Single Dose of MT-7117 in Subjects with Normal and Impaired Hepatic Function |
| NCT04402489 ↗ | Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoetic Protoporphyria or X-Linked Protoporphyria | Active, not recruiting | Mitsubishi Tanabe Pharma Development America, Inc. | Phase 3 | The primary objective of this study is to investigate the efficacy of MT-7117 on time to onset and severity of first prodromal symptoms (burning, tingling, or stinging) associated with sunlight exposure in subjects with EPP or XLP aged 12-75. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for MT-7117
Condition Name
Clinical Trial Locations for MT-7117
Trials by Country
Clinical Trial Progress for MT-7117
Clinical Trial Phase
Clinical Trial Sponsors for MT-7117
Sponsor Name
